Registry for patients with Generalized Pustular Psoriasis
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
CorEvitas · NCT06100991
This study is gathering information from people with Generalized Pustular Psoriasis to see how they are treated, how their condition changes over time, and any other health issues they might have.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CorEvitas (network) |
| Locations | 1 site (Waltham, Massachusetts) |
| Trial ID | NCT06100991 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to gather data on treatment patterns, disease progression, and the occurrence of comorbidities and adverse events in patients diagnosed with Generalized Pustular Psoriasis (GPP). Approximately 200 subjects will be recruited from 75 clinical sites across North America. The study will utilize standardized data collection methods, including validated patient-reported and clinician-reported outcomes, to better understand the natural history of GPP. Additionally, the registry will evaluate aspects such as clinical effectiveness, healthcare resource utilization, and patient adherence to treatments.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who have been diagnosed with GPP by a qualified dermatologist.
Not a fit: Patients currently participating in a blinded clinical trial for GPP treatment or enrolled in another CorEvitas registry will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could enhance understanding of GPP and improve treatment strategies for patients.
How similar studies have performed: Other observational registries have successfully provided valuable insights into chronic dermatological conditions, suggesting this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * A subject must meet all the following criteria to participate in the registry: 1. Has been diagnosed with GPP by a dermatologist or a qualified dermatology practitioner. 2. Is at least 18 years of age and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted. 3. Is willing to provide consent for participation in the registry. 4. Is willing to provide Personal Information Exclusion Criteria: * Any of the following would exclude the subject from participating in the registry: 1. Is participating or planning to participate in a blinded clinical trial evaluating a systemic agent for the treatment or prevention of flares related to GPP. 2. Is enrolled in another CorEvitas registry for a dermatological condition. Subjects enrolled in another CorEvitas registry must be exited to be eligible for enrollment into the GPP Registry
Where this trial is running
Waltham, Massachusetts
- CorEvitas, LLC — Waltham, Massachusetts, United States (RECRUITING)
Study contacts
- Study coordinator: Cathy Cheney
- Email: corevitasregistrytrials@corevitas.com
- Phone: +1 508 408 5433
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Generalized Pustular Psoriasis